GoBear is now part of Finder
Picture not described

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Vir Biotechnology (VIR) shares

Learn how to easily invest in Vir Biotechnology shares.

Vir Biotechnology Inc is a biotechnology business based in the US. Vir Biotechnology shares (VIR) are listed on the NASDAQ and all prices are listed in US Dollars. Vir Biotechnology employs 367 staff and has a trailing 12-month revenue of around USD$182.7 million.

How to buy shares in Vir Biotechnology

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – VIR – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Compare online brokers

Name Product Number of Stocks Shares Available Markets
Interactive Brokers
Access to global markets
Yes
Global markets
Your capital is at risk.
Saxo Markets
19,000+
Yes
Global markets
Your capital is at risk.
Plus500
2,000+
No
US, UK, AU, DE, FR, IT, PT, GR, JP, SG, ZA, NL, FI, BE, DK, SE, CH, ES, AT, NO, HU, CZ, IE, PL, HK
CFD Service. Your capital is at risk.
BlackBull Markets
N/A
No
UK, HK, JP, MY, NZ, US
CFD Service. Your capital is at risk.
Libertex
50+
No
Worldwide with exception.
Except for: US/Australia/New Zealand/Belgium/British Virgin Islands/Guam/Lebanon/United States Minor/Outlying Islands/Northern Mariana Islands/Uganda/Philippines/Sri Lanka/Kuwait/South Africa/Azerbaijan/Canada/Armenia/Russia/Japan/Brasil.
CFD Service. Your capital is at risk.
Exness
N/A
No
CH, VN, TH, PH, SG, ID, IN, UAE, ZA, SA, EG, BR, CR, MX
CFD Service. Your capital is at risk.
IG
17,000+
No
DK, IE, NO, RU, DE, IT, AT, CH, ES, LU, PT, SE, FR, NL, RO, UK, US, AU, JP, SG, ZA, AE
CFD Service. Your capital is at risk.
loading

Compare up to 4 providers

How has Coronavirus impacted Vir Biotechnology's stock price?

Since the stock market crash in March caused by coronavirus, Vir Biotechnology's stock price has had significant positive movement.

Its last market close was $39.09, which is 58.40% up on its pre-crash value of $16.26 and 142.95% up on the lowest point reached during the March crash when the stocks fell as low as $16.09.

If you had bought $1,000 worth of Vir Biotechnology stocks at the start of February 2020, those stocks would have been worth $1,605.35 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,714.10.

Is it a good time to buy Vir Biotechnology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Vir Biotechnology shares at a glance

Information last updated 2021-10-16.
Latest market close$39.09
52-week range$25.31 - $83.50
50-day moving average $45.21
200-day moving average $43.92
Wall St. target price$68.14
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.33

Vir Biotechnology stock price (NASDAQ: VIR)

Use our graph to track the performance of VIR stocks over time.

Vir Biotechnology price performance over time

Historical closes compared with the close of $39.09 from 2021-10-15

1 week (2021-10-11) -2.32%
1 month (2021-09-17) -28.33%
3 months (2021-07-17) -5.37%
6 months (2021-04-16) -15.72%
1 year (2020-10-16) -0.89%
2 years (2019-10-18) 186.16%
3 years (2018-10-14) N/A
5 years (2016-10-14) N/A

Vir Biotechnology financials

Revenue TTM $182.7 million
Gross profit TTM $-196,511,000
Return on assets TTM -18.69%
Return on equity TTM -45.71%
Profit margin -162.74%
Book value $5.65
Market capitalisation $5.1 billion

TTM: trailing 12 months

Shorting Vir Biotechnology shares

There are currently 5.2 million Vir Biotechnology shares held short by investors – that's known as Vir Biotechnology's "short interest". This figure is 8.1% down from 5.7 million last month.

There are a few different ways that this level of interest in shorting Vir Biotechnology shares can be evaluated.

Vir Biotechnology's "short interest ratio" (SIR)

Vir Biotechnology's "short interest ratio" (SIR) is the quantity of Vir Biotechnology shares currently shorted divided by the average quantity of Vir Biotechnology shares traded daily (recently around 858538.7888707). Vir Biotechnology's SIR currently stands at 6.11. In other words for every 100,000 Vir Biotechnology shares traded daily on the market, roughly 6110 shares are currently held short.

However Vir Biotechnology's short interest can also be evaluated against the total number of Vir Biotechnology shares, or, against the total number of tradable Vir Biotechnology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Vir Biotechnology's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Vir Biotechnology shares in existence, roughly 40 shares are currently held short) or 0.0744% of the tradable shares (for every 100,000 tradable Vir Biotechnology shares, roughly 74 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Vir Biotechnology.

Vir Biotechnology share dividends

We're not expecting Vir Biotechnology to pay a dividend over the next 12 months.

Vir Biotechnology share price volatility

Over the last 12 months, Vir Biotechnology's shares have ranged in value from as little as $25.31 up to $83.5. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Vir Biotechnology's is -1.314. This would suggest that Vir Biotechnology's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Vir Biotechnology has bucked the trend.

Vir Biotechnology overview

Vir Biotechnology, Inc. , a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. ; a collaboration, license, and option agreement with Visterra, Inc. ; license agreements with The Rockefeller University and MedImmune, Inc. ; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More guides on Finder

Ask Finder

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked
Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy Policy and Terms.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site